...
首页> 外文期刊>Histopathology: Official Journal of the British Division of the International Academy of Pathology >Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours.
【24h】

Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours.

机译:胰腺头腺癌的分化标志物:MUC1和MUC4表达表明胰腺胆管分化的肿瘤预后不良。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIMS: To examine how accurately immunohistochemical markers discriminate between pancreatobiliary and intestinal-type adenocarcinomas in the pancreatic head and to explore the prognostic importance of these markers among each of these histological types. METHODS AND RESULTS: Histopathological features of 114 consecutively resected adenocarcinomas of pancreatobiliary (n = 67) and intestinal (n = 47) type of differentiation were recorded according to a standardized protocol. Immunohistochemistry for cytokeratin (CK) 7, CK20, MUC1, MUC2, MUC4 and CDX2 was performed on tissue microarrays. Classification of the adenocarcinomas based on immunohistochemistry was compared with the morphological evaluation of histological type. Presence of CK7 and MUC4, and absence of CDX2, were independent predictors of pancreatobiliary versus intestinal type. Using these markers to optimize immunohistochemical classification, agreement between immunohistochemical and morphological classification was only moderate (kappa = 0.53). In pancreatobiliary differentiated tumours, MUC1 and/or MUC4 expression was an independent prognostic factor (hazard ratio 2.02, 95% confidence interval 1.02, 3.98) when adjusting for nodal involvement, vessel involvement and tumour size. In intestinally differentiated tumours, none of the markers was significantly associated with prognosis. CONCLUSIONS: Agreement between immunohistochemical and morphological classification of pancreatic head adenocarcinomas is moderate. In pancreatobiliary adenocarcinomas, MUC1 and/or MUC4 expression indicates a particularly poor prognosis.
机译:目的:检查免疫组织化学标志物在胰腺头中区分胰腺胆管癌和肠型腺癌的准确性,并探讨这些标志物在每种组织学类型中对预后的重要性。方法和结果:按照标准化方案记录了114例连续切除的胰腺胆管癌(n = 67)和肠癌(n = 47)类型的腺癌的组织病理学特征。在组织微阵列上进行了细胞角蛋白(CK)7,CK20,MUC1,MUC2,MUC4和CDX2的免疫组织化学。将基于免疫组织化学的腺癌分类与组织学类型的形态学评价进行比较。 CK7和MUC4的存在以及CDX2的缺失是胰腺胆道与肠道型的独立预测因子。使用这些标记物优化免疫组织化学分类,免疫组织化学和形态学分类之间的一致性仅为中等(kappa = 0.53)。在胰腺胆管分化肿瘤中,当调整淋巴结受累,血管受累和肿瘤大小时,MUC1和/或MUC4的表达是一个独立的预后因素(危险比2.02,95%可信区间1.02,3.98)。在肠道分化的肿瘤中,没有任何标志物与预后显着相关。结论:胰头腺癌的免疫组织化学和形态学分类之间的一致性中等。在胰腺胆腺癌中,MUC1和/或MUC4表达表明预后特别差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号